Annotation Detail
Information
- Associated Genes
- ROS1
- Associated Variants
- ROS1 CD74-ROS1 G2032R
- Associated Disease
- lung non-small cell carcinoma
- Source Database
- CIViC Evidence
- Description
- ROS1 kinase domain mutations were assessed in two patients with stage IIIa/IV pulmonary adenocarcinoma and a cell line. The ROS1 G2032R mutation was identified in a crizotinib-resistant tumor from one of the patients harboring the CD74–ROS1 fusion. Expression of CD74–ROS1 G2032R in Ba/F3 cells conferred resistance to crizotinib combared to CD74–ROS1 (IC50=353.62+/-20.15 vs. 2.76+/-0.82).
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1254
- Gene URL
- https://civic.genome.wustl.edu/links/genes/4941
- Variant URL
- https://civic.genome.wustl.edu/links/variants/465
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Lung Non-small Cell Carcinoma
- Evidence Direction
- Supports
- Drug
- Crizotinib
- Evidence Level
- C
- Clinical Significance
- Resistance
- Pubmed
- 25688157
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Crizotinib | Resitance or Non-Reponse | true |